Clinical Outcome and Safety of Bacillus Calmette-Guérin Immunotherapy for Superficial Bladder Cancer

By Morabito F.   Volpe A.   Rossi R.   Lasaponara F.   Ferrando U.  

UroOncology, Vol. 4, Iss. 2, 2004-06 ,pp. : 97-102

Ashgate Publishing Ltd

Access to resources Recommend Favorite

The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette–Guérin in Superficial Bladder Cancer: a Preliminary Study

By Cho DY   Bae JH   Moon DG   Cheon J   Lee JG   Kim JJ   Yoon DK   Park HS  

The Journal of International Medical Research, Vol. 37, Iss. 6, 2009-11 ,pp. : 1823-1830

Field House Publishing

Access to resources Recommend Favorite

Use of BCG in Immunotherapy of Superficial Bladder Cancer: Multicentric Investigation on Safety and Compliance

By Morgia Giuseppe   Falsaperla Mario   Madonia Massimo   Vacirca Franco   La Pira Giuseppe   De Grande Gaetano   Nicololosi Dario   Raciti Giovanni   Capizzi Giuseppe   Serrao Antonio   Torrisi Benedetto  

UroOncology, Vol. 2, Iss. 3, 2003-07 ,pp. : 129-135

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer: Molecular Mechanisms of Action

By  

Clinical Immunology, Endocrine & Metabolic Drugs, Vol. 3, Iss. 1, 2016-06 ,pp. : 31-38

Bentham Science Publishers

Access to resources Recommend Favorite

Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non–muscle-invasive bladder cancer

By Bachir Bassel G.   Dragomir Alice   Aprikian Armen G.   Tanguay Simon   Fairey Adrian   Kulkarni Girish S.   Breau Rodney H.   Black Peter C.   Kassouf Wassim  

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2424-2431

Blackwell Publishing

Access to resources Recommend Favorite